Azenta, Inc. is closing three laboratory facilities in North America and eliminating jobs under an operational restructuring plan approved by its board on 5 October [1]. The company, which provides automated sample exploration and multiomics services for life sciences, disclosed the plan in an SEC filing on 7 October [1].
The company estimates it will record $11 million to $13 million in aggregate pre-tax restructuring charges [1]. This includes approximately $9 million in non-cash asset impairment charges for leasehold abandonments and roughly $3 million in cash severance and employee transition costs [1]. Future cash expenditures associated with the plan are estimated at $7 million [1].
Azenta said it began notifying affected personnel on 6 October [1]. Actions under the plan are scheduled for substantial completion by 31 March 2027, with the company projecting approximately $11 million in annualized run-rate cost savings once the consolidation finishes [1].
What it measures
The filing counts facility closures and workforce reductions specifically within Azenta's Multiomics reportable segment across North America [1]. The company said the consolidation aims to simplify organizational reporting and improve laboratory operating margins following smaller, non-material workforce realignments completed in August and September [1].
What it does not tell you
The filing discloses total estimated cash severance expenditures ($3 million) but does not disclose the numerical count of employees being terminated [1]. It does not list the specific city locations of the three shuttered laboratory sites [1].
Comments